Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy

Скорочена інформація про документ
dc.contributor.authorGalbiatti, A.L.S.
dc.contributor.authorCaldas, H.C.
dc.contributor.authorPadovani Junior, J.A.
dc.contributor.authorPavarino, E.C.
dc.contributor.authorGoloni-Bertollo, E.M.
dc.date.accessioned2018-06-21T12:37:44Z
dc.date.available2018-06-21T12:37:44Z
dc.date.issued2012
dc.description.abstractAim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.uk_UA
dc.description.sponsorshipFundação de Amparo а Pesquisa do Estado de Sгo Paulo (FAPESP) for their financial support (Nє 2010/12930-4, 2010/12932-7); Prof. Dr. Moacir F. Godoy for their help in statistical analysis; Profa. Dra Eloiza Helena Tajara for providing of the cell line; Oncology Department, Hospital de Base, São José do Rio Preto for providing of the Methotrexate Chemotherapeutic; CNPQ (National Counsel of Technological and Scientific Development) and FAMERP/FUNFARME.uk_UA
dc.identifier.citationSensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ.uk_UA
dc.identifier.issn1812-9269
dc.identifier.urihttps://nasplib.isofts.kiev.ua/handle/123456789/139856
dc.language.isoenuk_UA
dc.publisherІнститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН Україниuk_UA
dc.relation.ispartofExperimental Oncology
dc.statuspublished earlieruk_UA
dc.subjectShort communicationsuk_UA
dc.titleSensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapyuk_UA
dc.typeArticleuk_UA

Файли

Оригінальний контейнер

Зараз показуємо 1 - 1 з 1
Ескіз
Назва:
17-Galbiatti.pdf
Розмір:
517.18 KB
Формат:
Adobe Portable Document Format
Завантажити

Контейнер ліцензії

Зараз показуємо 1 - 1 з 1
Ескіз
Назва:
license.txt
Розмір:
817 B
Формат:
Item-specific license agreed upon to submission
Опис:
Завантажити

Колекція

Experimental Oncology, 2012, № 4